{"id":"oral-roflumilast","safety":{"commonSideEffects":[{"rate":"15–25%","effect":"Nausea"},{"rate":"10–20%","effect":"Diarrhea"},{"rate":"5–15%","effect":"Headache"},{"rate":"5–10%","effect":"Weight loss"},{"rate":"5–10%","effect":"Vomiting"},{"rate":"2–5%","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL193240","moleculeType":"Small molecule","molecularWeight":"403.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE-4, roflumilast prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated cAMP concentrations in inflammatory cells such as macrophages, neutrophils, and T cells. This elevation suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing airway inflammation and mucus production. The drug is used to modulate chronic inflammatory airway diseases by dampening the underlying inflammatory cascade.","oneSentence":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:43.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) with chronic bronchitis"},{"name":"Asthma (investigational)"}]},"trialDetails":[{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT07314242","phase":"PHASE2","title":"A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD","status":"NOT_YET_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2026-01-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":120},{"nctId":"NCT07297602","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study","status":"RECRUITING","sponsor":"Nora Mohamed Abdelrazik","startDate":"2025-11-20","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT07233291","phase":"PHASE2","title":"A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults","status":"RECRUITING","sponsor":"Ahmed Ibrahim","startDate":"2025-08-20","conditions":"Psoriasis (PsO)","enrollment":36},{"nctId":"NCT07174011","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-01-12","conditions":"Alopecia, Alopecia Areata","enrollment":50},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT05684484","phase":"PHASE4","title":"Role of Roflumilast in Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT04322929","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study (2019)","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-11-12","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":42},{"nctId":"NCT06677788","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-04-01","conditions":"Non-Alcoholic Steatohepatitis (NASH)","enrollment":55},{"nctId":"NCT06652776","phase":"","title":"The Italian Registry of Patients with Chronic Obstructive Pulmonary Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University of Milan","startDate":"2024-09-30","conditions":"COPD, COPD Exacerbation Acute, Comorbid Chronic Lung Disease on Heart Failure","enrollment":10000},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT05796271","phase":"PHASE1","title":"Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03458546","phase":"PHASE1","title":"Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-21","conditions":"Lymphoma, B-Cell","enrollment":14},{"nctId":"NCT04854811","phase":"PHASE2","title":"Roflumilast to Treat Cognitive Sequela After Stroke","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2021-07-07","conditions":"Cerebrovascular Disorders, Memory, Functional Recovery","enrollment":100},{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":"Type 2 Diabetes (Adult Onset), Diabetic Neuropathies","enrollment":60},{"nctId":"NCT05682859","phase":"PHASE4","title":"Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)","status":"RECRUITING","sponsor":"Jacob Pontoppidan Thyssen","startDate":"2023-09-25","conditions":"Chronic Hand Eczema","enrollment":40},{"nctId":"NCT04108377","phase":"PHASE1","title":"Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2019-01-21","conditions":"Asthma","enrollment":5},{"nctId":"NCT05684744","phase":"PHASE2, PHASE3","title":"Roflumilast Versus Methotrexate in Psoriasis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-01-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03532490","phase":"PHASE2","title":"Trial of Roflumilast in Asthma Management (TRIM)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-03","conditions":"Asthma, Obesity","enrollment":38},{"nctId":"NCT04658654","phase":"PHASE2","title":"Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2021-11-19","conditions":"Mild Cognitive Impairment, Mild Dementia, Amnestic Mild Cognitive Disorder","enrollment":81},{"nctId":"NCT04369547","phase":"PHASE1","title":"Roflumilast TMS-EEG Plasticity","status":"WITHDRAWN","sponsor":"University of Calgary","startDate":"2022-01","conditions":"Synaptic Plasticity","enrollment":""},{"nctId":"NCT03988816","phase":"PHASE2","title":"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-12-06","conditions":"Bronchiectasis Adult","enrollment":30},{"nctId":"NCT01509677","phase":"PHASE3","title":"Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-02-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT04122547","phase":"PHASE3","title":"Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2015-01","conditions":"Exacerbation Copd, Bronchiectasis, Lung Function Decreased","enrollment":40},{"nctId":"NCT03428334","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-05-10","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":20},{"nctId":"NCT02671942","phase":"PHASE2","title":"A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":55},{"nctId":"NCT01630200","phase":"PHASE4","title":"Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease and Allied Conditions","enrollment":80},{"nctId":"NCT02340520","phase":"PHASE3","title":"Enhancement of Corticosteroid Efficacy in COPD","status":"COMPLETED","sponsor":"UConn Health","startDate":"2014-12","conditions":"COPD","enrollment":13},{"nctId":"NCT02097992","phase":"PHASE1, PHASE2","title":"Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD","status":"COMPLETED","sponsor":"University of Miami","startDate":"2013-02","conditions":"COPD","enrollment":11},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01443845","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-30","conditions":"COPD, COPD Exacerbation, Lung Diseases","enrollment":2354},{"nctId":"NCT01888952","phase":"EARLY_PHASE1","title":"Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)","status":"COMPLETED","sponsor":"Anand B. Karnad","startDate":"2013-07","conditions":"Advanced B-cell Lymphoid Malignancies","enrollment":10},{"nctId":"NCT01473758","phase":"PHASE2","title":"Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-02","conditions":"Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation","enrollment":81},{"nctId":"NCT01313494","phase":"PHASE3","title":"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"COPD","enrollment":626},{"nctId":"NCT01765192","phase":"PHASE2","title":"Roflumilast Plus Montelukast in Adults With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Asthma","enrollment":64},{"nctId":"NCT02051335","phase":"PHASE1","title":"Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Memory Impairment, Alzheimer's Disease","enrollment":27},{"nctId":"NCT01703260","phase":"PHASE2","title":"Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Nonalcoholic Steatohapatitis","enrollment":20},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT00297102","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1523},{"nctId":"NCT00313209","phase":"PHASE3","title":"Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT00424268","phase":"PHASE3","title":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT00940329","phase":"PHASE1","title":"Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Healthy","enrollment":27},{"nctId":"NCT00163527","phase":"PHASE3","title":"Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":2054},{"nctId":"NCT00242320","phase":"PHASE3","title":"Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"COPD","enrollment":551},{"nctId":"NCT00297115","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1568},{"nctId":"NCT01285167","phase":"","title":"Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3645},{"nctId":"NCT01285180","phase":"","title":"Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-08","conditions":"Severe COPD","enrollment":5472},{"nctId":"NCT01354782","phase":"PHASE1","title":"Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":32},{"nctId":"NCT00073177","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":819},{"nctId":"NCT01365533","phase":"PHASE2","title":"A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Allergic Asthma","enrollment":48},{"nctId":"NCT02079844","phase":"PHASE1","title":"Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT01572948","phase":"NA","title":"A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-06","conditions":"COPD","enrollment":27},{"nctId":"NCT01701934","phase":"PHASE2","title":"Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Laval University","startDate":"2013-02","conditions":"Chronic Obstructive Pulmonary Disease, Metabolic Syndrome","enrollment":14},{"nctId":"NCT02187250","phase":"PHASE4","title":"PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-03","conditions":"PCOS, Obesity","enrollment":45},{"nctId":"NCT02037672","phase":"PHASE4","title":"PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2013-09","conditions":"PCOS, Obesity","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daxas","EU: Daxas","US: Daliresp","PDE4 inhibitor","ARQ-151"],"phase":"phase_3","status":"active","brandName":"Oral roflumilast","genericName":"Oral roflumilast","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells. Used for Chronic obstructive pulmonary disease (COPD) with chronic bronchitis, Asthma (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}